Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Adverse prognostic features & treatment response in CLL

Thomas Kipps • 9 Jun 2023
EHA 2023
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors Ibrutinib

Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, comments on the use of genomics to identify poor prognostic features in chronic lymphocytic leukemia (CLL), highlighting the potential to convert a poor risk feature into a favorable risk feature with the use of targeted therapies or novel combination therapies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Thomas Kipps

1:28
A long-term analysis of lenalidomide and rituximab for the treatment of CLL
Thomas Kipps • 11 Dec 2023
1:35
Ven-based regimens for R/R CLL and considering an MRD-guided strategy
Thomas Kipps • 11 Dec 2023
1:18
The use of genomics to help select treatment in CLL
Thomas Kipps • 9 Jun 2023
2:12
Understanding and overcoming resistance to BTK and BCL-2 inhibitors in CLL
Thomas Kipps • 9 Jun 2023

Related Videos

5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
2:02
Relapse incidence post-alloSCT with PTCy for AML in CR1
Arnon Nagler • 16 Apr 2024
1:35
Outcomes of alloSCT following blinatumomab in children and young adults with R/R B-ALL
Mattia Algeri • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals